1Anstee QM, Wright M, Goldin R, et al. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clin Liver Dis, 2009, 13: 117-126.
2Okuda K, Ohnishi K, Kimura K, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology, ! 985,89 : 279-286.
3Fujita K, Nozaki Y, Wada K, et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut, 2008,57: 1583-1591.
4Ganey PE, Luyendyk JP, Newport SW, et al . Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology, 2007,46 : I 177-1186.
5Anstee QM, Goldin RD, Wright M, et al. Thursz Coagulation status modulates murine hepatic fibrogenesis implications for the development of novel therapies. J Thromb Haemost, 2008, 6: 1336-1343.
6Villa E, Camma C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology, 2012,143: 1253-1260.
7Tsochatzis EA, Senzolo M, Germani G, et al. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther, 2010, 31: 366-374.
8Rodriguez-Castro KI, Porte RJ, Nadal E, et al. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. Transplantation, 2012, 94 1145-1153.
9Senzolo M, Sartori TM, Rossetto V, et al. Prospective evaluation of antieoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int, 2012, 32: 919-927.
10Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol, 2012, 10 : 776-783.
